AI summary by TwinMind

Why Gene Therapy is So Expensive

Asianometry

19m 29s

Introduction to Gene Therapy Complexity

  • Gene therapies = most expensive drugs in world
  • Producing viral vectors for in-vivo gene therapy = most complicated process ever attempted at scale in bio-pharmaceuticals
  • Goal: transfer genetic material to target cells to add, suppress, or edit genes
  • Vehicles for gene delivery called vectors

Early Non-Viral Gene Transfer Methods (1960s-1980s)

  • 1962: Polish-American scientist Vox CLA Silasi & Elizabeth Obasa pioneered gene transfer method
  • Used famous HeLa cell line to test if mammalian cells can pass foreign genes to next generation
  • Problem: both genes and cell membranes negatively charged
  • Solution: calcium phosphate co-precipitation method
    • Added positively charged calcium ions to DNA
    • Reduced negative charge enough for cell entry
  • Widely used as vector in lab setting 1970s-1980s
  • Impractical for in-vivo gene therapy treatments:
    • Inefficient even in controlled lab conditions
    • No targeting mechanism for specific cells in body
    • DNA physically fragile, deteriorates in blood/tissue environment
    • Calcium phosphate triggers immune responses or clumps together

Discovery of Viral Gene Transfer (1950s-1960s)

  • Viruses known to carry genes since early 1950s
  • 1952: Norton Zinder & Nobel Prize winner Joshua Lederberg published experiment
    • Discovered small particles can move traits between Salmonella bacteria populations
    • Concluded agent was virus due to tiny size and antibiotic resistance
    • Named process "transduction"
  • 1966: Nobel Prize winner Edward Tatum's speech first publicly proposed using modified viruses for healing genes
    • Suggested DNA transformation/transduction could work with animal cells
    • Would facilitate mammalian somatic cell genetics development
    • Bring closer to successful genetic engineering

First Human Gene Therapy Trials (1970s)

  • Mid-1970s: Two girls in West German village with rare genetic defect
    • Bodies couldn't produce arginase enzyme
    • Arginase breaks down arginine; excess causes seizures and mental retardation
  • Professor E. Stanfield Rogers at Oak Ridge Lab worked with Shope papilloma virus
    • Infected rabbits grew horns on faces/necks
    • Also produced elevated amounts of different arginase type
    • Lab workers accidentally infected showed similar results
  • Rogers proposed injecting girls with Shope virus
  • Trial failed: only created severe but temporary allergy in one child
  • Later genome sequencing revealed virus had no arginase gene for humans
  • Effects likely from heightened immune response to virus

First Successful Gene Therapy (1990)

  • September 1990: FDA approved first gene therapy trial for therapeutic effect
  • Two girls with severe combined immunodeficiency (SCID) - "Bubble Boy syndrome"
    • Deficiency in adenosine deaminase
    • Previously, infants died within first 2 years of life
  • Team led by Michael Blaese used retrovirus-based treatment
    • Extracted T-cells from girls
    • Used disabled Moloney murine leukemia retrovirus to inject new genes
    • Modified cells injected back into girls' bone marrow
  • Girls received multiple infusions over 2 years
  • After 5 years: one girl showed T-cell count recovery, other minimal effects
  • No serious negative side effects
  • Difficult to determine if genetic therapy worked (patient also received enzyme therapy)
  • Experiment seen as major step forward, opened door to other SCID gene therapy trials

Retrovirus Challenges and Safety Concerns

  • Early therapies used retroviruses (RNA viruses with reverse transcriptase)
  • Initially chosen for ability to insert genes into cell genome
  • Industry moved away due to limitations:
    • Only target dividing cells (most vulnerable to intrusion)
    • Limited to stem cell therapies like T-cells for SCID
  • Safety concerns: insertional mutagenesis risk
    • Gene insertion can disrupt other genes
    • Can activate cancer-causing oncogenes
  • 2008 paper: 10 SCID patients received gene therapy
    • 9 treatments successful
    • 4 of 9 patients developed leukemia few years after treatment

Adenovirus Vectors: Benefits and Tragic Failure

  • Adenoviruses emerged as potential replacement for retroviruses
  • Large double-stranded viruses causing common cold to serious diseases
  • Advantages over retroviruses:
    • Much larger capacity: 36,000 base pairs DNA vs 8,000 for retroviruses
    • Don't require dividing cells for infection (expanded target range)
    • Genes remain episomal (separate from genome like loose leaf paper)
    • Minimized cancer risks
  • Major risk: immunogenic (trigger big immune response)

Jesse Gelsinger Tragedy (1999)

  • 18-year-old Jesse Gelsinger signed up for University of Pennsylvania trial
  • Had mild OTC deficiency (affects body's ability to break down ammonia)
  • Condition manageable with diet and pills
  • Received adenovirus-based gene treatment
  • Vector transferred <1% of desired genes to right cells
  • Given highest dose: 38 trillion viral particles
  • Virus had genes removed (couldn't replicate) but still immunogenic
  • Large dose triggered massive immune response and multi-organ failure
  • Gelsinger died
  • Serious lapses discovered: trial protocol violations, financial conflicts, informed consent issues
  • Lawsuits filed
  • Largely ended adenovirus use for most gene therapies in US
  • Still used for cancer therapies where immunogenic status is beneficial

First Approved Gene Therapy (2003)

  • 2003: China's State Food and Drug Administration approved Gendicine
  • Adenovirus cancer therapy for head and neck cancers
  • Neither US nor EU approved it

Lentivirus Development

  • Industry adopted new viral vectors post-tragedy with renewed safety focus
  • Lentiviruses = subset of retroviruses (HIV is lentivirus)
  • Small size and sustained gene expression ability
  • Top choice for ex-vivo cell treatments (cells treated outside body then returned)
  • Great benefit for X-linked adrenoleukodystrophy (ALD) treatment
    • Characterized by fatty acid buildup in nervous system
    • Can lead to vegetative state and death
    • Featured in 1992 movie "Lorenzo's Oil"
  • 2007: first gene therapy trials for ALD
  • FDA granted breakthrough status to several treatments
  • Retrovirus oncogene activation threat remains

Adeno-Associated Viruses (AAVs): Current Standard

  • Most therapies moved to modified adeno-associated viruses (AAVs)
  • Discovered 1960s as contaminants in adenovirus cell lines
  • Key characteristics:
    • Very small: ~25 nanometers wide
    • Hold far fewer DNA: up to 5,000 bases (newer versions under development for higher capacity)
    • Cannot replicate without helper functions from adenoviruses
    • Travel with adenoviruses like "parasite to a virus"
    • Never seen to cause disease
    • Generally don't cause toxicity or immunogenic issues (unless repeatedly administered)
  • Scientists started working with them mid-1980s
  • Can hang around like drone until able to inject payload
  • First AAV trials 1990s targeted cystic fibrosis gene (success remains elusive)

First AAV Approval: Glybera (2012)

  • EU approved Glybera 2012 after 3 prior rejections
  • Treatment for lipoprotein lipase deficiency
  • Gained negative press for costing over $1 million
  • Later withdrawn - only 31 people ever received drug

Current AAV Manufacturing Challenges

  • 200+ trials in progress for AAVs (dominant platform)
  • Applicable to other virus vectors like lentiviruses
  • Astoundingly complicated to produce due to stripped-down nature

Upstream Processes

  • Produce raw viruses in mass
  • Coordinate expression of 10+ virus genes from AAV and co-infection viruses
  • Amplify therapeutic gene payload accurately in high volume
  • Ensure sufficient quantities of all components
  • Assemble components inside host cells:
    • Usually embryonic kidney cell line HEK 293
    • Or insect cells
  • Transfect host cells with components
  • Ferment cells in bioreactors 48-72 hours
  • Assembly process inside host cells poorly understood
  • Cannot easily optimize process

Poor Yields

  • Yields remain very low
  • Majority of host cell production = empty capsids (protein envelopes without genes)
  • <10,000 complete viruses produced per batch
  • Yield only 5-30% of total production
  • Only percentage of complete viruses actually infectious
  • Per 2023 paper: very disappointing results

Downstream Processes

  • Extract and purify AAVs to meet FDA standards
  • Harvest host cells (may require lysis to release AAV particles)
  • Filter out impurities:
    • Cell debris
    • Empty capsids
    • Host cell DNA strands
    • Other contaminants
  • Multi-step purification process:
    • Filters and ultracentrifugation (>150,000 RPM to separate by weight)
    • Series of chromatography steps (separate by charge, hydrophobicity, size)
  • Purify results and formulate for stability
  • Extensive downstream processes further reduce yields
  • Necessary to ensure dose safety and efficacy

Economic Challenges

  • Gene therapy costs $1+ million per treatment
  • Multiple factors contribute to high costs:
    • Rigorous regulation (makes sense given history)
    • Small patient populations
    • Pool shrinks if therapy successful
  • Primary cost driver: manufacturing
    • Doses cost $300K+ to manufacture
    • Each production run yields <20% usable virus
    • Can't scale up batches (risk losing consistency)
    • Single dose may require up to dozen runs or parallelization
  • Many gene therapy companies struggle to turn profit despite high prices

Future Manufacturing Needs

  • Industry searching for rapid, high-throughput viral manufacturing platform
  • Need quality monitoring systems like semiconductor fabs
  • Opportunity exists but strict regulation and conservative industry nature makes adoption difficult
  • Long-term economic sustainability of $1-3 million price tags questionable
  • Changes may be forced upon industry soon

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome